Major players in the microbiome therapeutics market are Seres Therapeutics, Enterome Bioscience, Rebiotix, Microbiome Therapeutics, and Ritter Pharmaceuticals.
The global microbiome therapeutics market is expected to grow from $0.29 billion in 2021 to $0.39 billion in 2022 at a compound annual growth rate (CAGR) of 34.7%. The microbiome therapeutics market is expected to grow to $1 billion in 2026 at a compound annual growth rate (CAGR) of 26.4%.
The microbiome therapeutics market consists of sales of microbiome therapeutics and related services by entities (organizations, sole traders, partnership) which are used to treat and prevent various diseases. The microbiome comprises the genetic material within a microbiota which is an entire collection of microorganisms found in and on all multicellular organisms.
The main products of microbiome therapeutics are probiotics, prebiotics, symbiotics, and other products. Probiotics are a combination of live beneficial bacteria and/or yeasts that naturally live in the body. The various distribution channels involved are hospital pharmacies, drug stores, retail pharmacies, and e-commerce stores. The applications included are inflammatory bowel disease, diabetes, multiple sclerosis, rheumatoid arthritis, and other applications.
The rising prevalence of obesity is expected to propel the growth of the microbiome therapeutics market. Sedentary lifestyles, busy work lives, and unhealthy food choices are gradually becoming the leading causes of obesity globally. Growing urbanization and busy lifestyles are leading to an increasing preference for packaged and processed food and physical inactivity. Microbiome therapeutics help prevents and treats diabetes by regulating sugar levels. For instance, in 2022, according to UK Parliament, a survey found that men are more likely than women to be overweight or obese (68.2% of men, 60.4% of women). People aged 45-74 are most likely to be overweight or obese. Therefore, the rising prevalence of obesity is driving the growth of microbiome therapeutics.
Increased research and development are a key trend gaining popularity in the microbiome therapeutics market. Companies operating in the microbiome therapeutics market are focused on developing new innovations to increase their market share. For instance, in March 2022, Microbiotica, a UK-based company raised $67 million in a Series B round to push two microbiome-based lead assets through phase 1b trials, slated to start this year.
In April 2022, Xbiome Inc, a China-based artificial intelligence microbiome therapeutics startup acquired a clinical-stage M201 program from Assembly Biosciences, Inc for an undisclosed amount. This acquisition reflects Xbiome’s commitment as one of the leaders in the rising field of microbiome therapeutics. Assembly Biosciences Inc is a US-based clinical-stage biotechnology company.
The countries covered in the microbiome therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, USA.
This product will be delivered within 3-5 business days.
The global microbiome therapeutics market is expected to grow from $0.29 billion in 2021 to $0.39 billion in 2022 at a compound annual growth rate (CAGR) of 34.7%. The microbiome therapeutics market is expected to grow to $1 billion in 2026 at a compound annual growth rate (CAGR) of 26.4%.
The microbiome therapeutics market consists of sales of microbiome therapeutics and related services by entities (organizations, sole traders, partnership) which are used to treat and prevent various diseases. The microbiome comprises the genetic material within a microbiota which is an entire collection of microorganisms found in and on all multicellular organisms.
The main products of microbiome therapeutics are probiotics, prebiotics, symbiotics, and other products. Probiotics are a combination of live beneficial bacteria and/or yeasts that naturally live in the body. The various distribution channels involved are hospital pharmacies, drug stores, retail pharmacies, and e-commerce stores. The applications included are inflammatory bowel disease, diabetes, multiple sclerosis, rheumatoid arthritis, and other applications.
The rising prevalence of obesity is expected to propel the growth of the microbiome therapeutics market. Sedentary lifestyles, busy work lives, and unhealthy food choices are gradually becoming the leading causes of obesity globally. Growing urbanization and busy lifestyles are leading to an increasing preference for packaged and processed food and physical inactivity. Microbiome therapeutics help prevents and treats diabetes by regulating sugar levels. For instance, in 2022, according to UK Parliament, a survey found that men are more likely than women to be overweight or obese (68.2% of men, 60.4% of women). People aged 45-74 are most likely to be overweight or obese. Therefore, the rising prevalence of obesity is driving the growth of microbiome therapeutics.
Increased research and development are a key trend gaining popularity in the microbiome therapeutics market. Companies operating in the microbiome therapeutics market are focused on developing new innovations to increase their market share. For instance, in March 2022, Microbiotica, a UK-based company raised $67 million in a Series B round to push two microbiome-based lead assets through phase 1b trials, slated to start this year.
In April 2022, Xbiome Inc, a China-based artificial intelligence microbiome therapeutics startup acquired a clinical-stage M201 program from Assembly Biosciences, Inc for an undisclosed amount. This acquisition reflects Xbiome’s commitment as one of the leaders in the rising field of microbiome therapeutics. Assembly Biosciences Inc is a US-based clinical-stage biotechnology company.
The countries covered in the microbiome therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, USA.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Microbiome Therapeutics Market Characteristics26. Key Mergers And Acquisitions In The Microbiome Therapeutics Market27. Microbiome Therapeutics Market Trends And Strategies28. Microbiome Therapeutics Market Future Outlook and Potential Analysis
3. Microbiome Therapeutics Market Size And Growth
4. Microbiome Therapeutics Market Segmentation
5. Microbiome Therapeutics Market Regional And Country Analysis
6. Asia-Pacific Microbiome Therapeutics Market
7. China Microbiome Therapeutics Market
8. India Microbiome Therapeutics Market
9. Japan Microbiome Therapeutics Market
10. Australia Microbiome Therapeutics Market
11. Indonesia Microbiome Therapeutics Market
12. South Korea Microbiome Therapeutics Market
13. Western Europe Microbiome Therapeutics Market
14. UK Microbiome Therapeutics Market
15. Germany Microbiome Therapeutics Market
16. France Microbiome Therapeutics Market
17. Eastern Europe Microbiome Therapeutics Market
18. Russia Microbiome Therapeutics Market
19. North America Microbiome Therapeutics Market
20. USA Microbiome Therapeutics Market
21. South America Microbiome Therapeutics Market
22. Brazil Microbiome Therapeutics Market
23. Middle East Microbiome Therapeutics Market
24. Africa Microbiome Therapeutics Market
25. Microbiome Therapeutics Market Competitive Landscape And Company Profiles
29. Appendix
Executive Summary
Microbiome Therapeutics Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global Microbiome Therapeutics market.This report focuses on Microbiome Therapeutics market which is experiencing strong growth. The report gives a guide to the Motors And Generators market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:
Where is the largest and fastest growing market for the Microbiome Therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Microbiome Therapeutics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider Microbiome Therapeutics market, and compares it with other markets.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
- Market segmentations break down market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
- The Microbiome Therapeuticsmarket section of the report gives context. It compares the Microbiome Therapeuticsmarket with other segments of the Microbiome Therapeuticsmarket by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, Microbiome Therapeuticsindicators comparison.
Scope
Markets Covered:
1) By Product: Probiotics; Prebiotics; Symbiotics; Other Products2) By Application: Inflammatory Bowel Disease; Diabetes; Multiple Sclerosis; Rheumatoid Arthritis; Other Applications
3) By Distribution Channel: Hospital Pharmacies; Drug stores; Retail Pharmacies; E-commerce stores Companies Mentioned: Qualcomm, Intel Corporation, Ericsson, Samsung, AT&T
Companies Mentioned: Seres Therapeutics; Enterome Bioscience; Rebiotix; MicroBiome Therapeutics and Ritter Pharmaceuticals.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
"
Companies Mentioned
- Seres Therapeutics
- Enterome Bioscience
- Rebiotix
- MicroBiome Therapeutics
- Ritter Pharmaceuticals
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | September 2022 |
| Forecast Period | 2022 - 2026 |
| Estimated Market Value ( USD | $ 0.39 Billion |
| Forecasted Market Value ( USD | $ 1 Billion |
| Compound Annual Growth Rate | 26.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 5 |
